Clinical Trial

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 4, 2026 (before its estimated July 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy and safety of HLX43 (Anti-PD-L1 ADC) in Combination with Serplulimab (Anti-PD-1 Recombinant Humanized Monoclonal Antibody) as Neoadjuvant Therapy in Subjects with Non-Small Cell Lung Cancer (NSCLC)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-26; most recent amendment 2026-06-02.
Status change: Not Yet Recruiting → Recruiting 2026-01-20
Trial Details
NCT Number NCT07269782
Lead Sponsor Shanghai Henlius Biotech
Conditions Non Small Cell Lung Cancer
Enrollment 60 participants
Start Date 2026-01-20
Primary Completion 2026-07-10 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-04